Idiosyncratic drug hepatotoxicity
The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Items 801–900 of 999
Drug Induced Liver Disease: Mechanisms and Diagnosis
Andrade, R. J., & Lucena, M. I. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch47 · Cited by 3
Predicting Drug‐Induced Hepatotoxicity: In Vitro , In Silico and In Vivo Approaches
Xu, J. J., Kalgutkar, A. S. S., Will, Y., Dykens, J. A., Tengstrand, E., & Hsieh, F. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch15 · Cited by 3
Discovery Toxicology Screening: Predictive,In VitroCytotoxicity
O'Brien, P. J. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch14 · Cited by 3
Li, A. P. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch3 · Cited by 3
Species-specific differences in acetaminophen hepatotoxicity depend on HSP70 expression level
Tsuji, D., & Akagi, R. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae086 · Cited by 2
Liu, H., Yang, Z., Li, J., Zhang, J., & Sun, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177381 · Cited by 2
Update and ADMET Profile of the Latin American Natural Product Database: LANaPDB
Gómez‐García, A., Lavecchia, M. J., Olmedo, D. A., Solís, P. N., & Medina‐Franco, J. L. (2025) · Molecular Informatics · doi:10.1002/minf.70013 · Cited by 4
Wang, F., Bai, S., Liu, S., Chen, Y., CHEN, L. ‐., Lv, X., & Wan, S. (2026) · ChemistrySelect · doi:10.1002/slct.202503433 · Cited by 2
Immunological aspects of drug-induced liver injury
Tajiri, K., & Shimizu, Y. (2014) · World Journal of Immunology · doi:10.5411/wji.v4.i3.149 · Cited by 2
Yun, S. Y., Kim, J. Y., Back, M. J., Kim, H. S., Ha, H. C., Jang, J. M., & Kim, D. K. (2019) · Molecular & Cellular Toxicology · doi:10.1007/s13273-019-0031-y · Cited by 2
A new design of coculture microfluidic chip for HepG2 and LO2 cells
Li, Y., Hu, Y., Huang, H., Meng, J., & Sun, Y. L. (2023) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2023.09.006 · Cited by 2
Drug-induced liver injury secondary to tamoxifen
Subhaharan, D., Murphy, G., Commins, N., & Azer, M. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-260098 · Cited by 2
Toxicity profile of standardized Krishna Vajra Abhraka bhasma made from biotite mica
Pandit, V. A., Singhal, S. K., Deshmane, G. B., Sahasrabuddhe, R. A., Karandikar, M., Pawar, M. S., Kulkarni, V. S., Dawane, J. S., & Wele, A. (2024) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2024.100980 · Cited by 4
Sung, I., Lee, S., Bang, D., Yi, J., Lee, S., & Kim, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398370 · Cited by 2
Biochemical Investigations on the Protective Role of Curcumin in Liver Damage by Chloroquine
Saifi, M. A., Alyousif, M. S., & Ahmed, M. (2015) · International Journal of Pharmacology · doi:10.3923/ijp.2015.870.873 · Cited by 2
Chapter 2 Drug-Induced Hepatotoxicity: Learning from Recent Cases of Drug Attrition
Pähler, A., & Funk, C. (2008) · Advances in molecular toxicology · doi:10.1016/s1872-0854(07)02002-4 · Cited by 2
Hepatic Bioactivation and Drug-Induced Liver Injury
Kemper, R. A., & Lai, G. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_11 · Cited by 3
Cosgrove, B. D., Alexopoulos, L. G., Hang, T.-C., Hendriks, B. S., Sorger, P. K., Griffith, L. G., & Lauffenburger, D. A. (2010) · Molecular BioSystems · doi:10.1039/b926287c · Cited by 59
Complicity of haem in some adverse drug-reactions
Vágány, V., & Smith, A. G. (2015) · Toxicology Research · doi:10.1039/c5tx00011d · Cited by 3
Posible asociación entre eritromicina y hepatitis colestásica
Mondragón-Navarro, M., Raurich, J. M., Ayestarán, I., Colomar, A., & Ferreruela, M. (2015) · Medicina Intensiva · doi:10.1016/j.medin.2015.10.001 · Cited by 2
Ikeda, T. (2006) · Folia Pharmacologica Japonica · doi:10.1254/fpj.127.454 · Cited by 2
Immunotoxicogenomics: Gene Expression and Immunotoxicology in the Age of Genomics
Germolec, D. R., Burns‐Naas, L. A., Gerberick, G. F., Ladics, G. S., Ryan, C. A., Pruett, S. B., Yücesoy, B., & Luebke, R. W. (2008) · CRC Press eBooks · doi:10.3109/9781420067064-12 · Cited by 2
Toxicogenomics in Preclinical Development
Fuchs, T., Truisi, G. L., & Hewitt, P. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00035-6 · Cited by 3
Ware, B. R., & Khetani, S. R. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_16 · Cited by 2
Bekker, Z., Walubo, A., & du Plessis, J. B. (2016) · Advances in Pharmacological Sciences · doi:10.1155/2016/3094783 · Cited by 2
Daly, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12382-0 · Cited by 3
Detection of Hepatotoxicity in Clinical and Experimental Settings
Harrill, A. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64265-4 · Cited by 2
Role of Endoplasmic Reticulum Stress in Hepatic Injury
Ji, C., Kaplowitz, N., & Han, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-58106-4_10 · Cited by 2
Self-citationThe Critical Role of Mitochondria in Drug-Induced Liver Injury
Decker, C. W., Casian, J. G., Nguyen, K. T., Horton, L. A., Rao, M. P., Silkwood, K. H., & Han, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-58106-4_8 · Cited by 2
Hepatic Injuries Induced by Engineered Nanomaterials
Jia, J., & Yan, B. (2017) · Nanomedicine and nanotoxicology · doi:10.1007/978-981-10-5864-6_12 · Cited by 2
Lee, H., Lee, S., Kang, J. W., & Lee, J. M. (2018) · Phytotherapy Research · doi:10.1002/ptr.6111 · Cited by 2
The role of medicinal chemistry in the drug discovery process
Beswick, P., & NAYLOR, A. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4299-7.00009-3 · Cited by 2
Avigan, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00038-8 · Cited by 2
Toxicogenomics in Preclinical Development
Fuchs, T., Truisi, G. L., & Hewitt, P. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00034-7 · Cited by 2
Mo, Z., Lei, Z., Wang, P., Wu, Z.-B., Yuan, H., Xie, D., Wu, Z., & Huang, Z. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101631 · Cited by 2
Fulminant Hepatic Failure: Diagnosis and Management
Marzio, D. H., & Sass, D. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-07209-8_16 · Cited by 2
(2007) · CRC Press eBooks · doi:10.3109/9781420021141-2 · Cited by 2
Hepatoxicity induced by clozapine: Case report and brief review
Revilla-Zúñiga, J. A., Carpio, J. C.-D., & Cruzado, L. (2023) · Revista Colombiana de Psiquiatría (English ed ) · doi:10.1016/j.rcpeng.2021.04.005 · Cited by 2
Hepatitis tóxica asociada al uso de medroxiprogesterona
Hidalgo, S. F., de Paula, J. M. P., & Valdivieso, I. S. (2009) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2008.06.001 · Cited by 2
Lesión hepática inducida por fármacos secundaria al uso de esteroides anabólicos
Díaz-García, J. D., Córdova‐Gallardo, J., Torres-Viloria, A., Estrada-Hernández, R., & Torre-Delgadillo, A. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2019.01.003 · Cited by 2
Mukai, M., Bischoff, K. L., & Ramaiah, S. K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385926-6.00017-x · Cited by 2
Woolbright, B. L., Williams, C. D., McGill, M. R., & Jaeschke, H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00205-1 · Cited by 4
Metabolite Profiling and Structural Identification
Moghaddam, M. F. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse057 · Cited by 2
Fundamental Principles of Toxicogenomics
Semizarov, D., & Blomme, E. A. G. (2008) · Wiley eBooks · doi:10.1002/9780470409770.ch4 · Cited by 2
Application of DNA Microarray in Studies of Herbal Dietary Supplements
Guo, L., Fuscoe, J. C., Fu, P. P., & Mei, N. (2009) · Wiley eBooks · doi:10.1002/9780470744307.gat225 · Cited by 3
Baier, V., Cordes, H., Thiel, C., Neumann, U. P., Blank, L. M., & Kuepfer, L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/450965 · Cited by 2
Graffmann, N., Spitzhorn, L., Ncube, A., Wruck, W., & Adjaye, J. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-33923-4_11 · Cited by 1
Alley, J., Jibril, A. N., Saleh, S. M., Umar, M., & Sirajo, M. U. (2023) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2023-0002 · Cited by 1
Idiosyncratic drug reactions and toxicities
Gupta, T., Wankhede, Y., Tekade, M., Singh, A., Vasdev, N., Pawar, B., Kumar, M., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00008-9 · Cited by 1
Soluyanova, P., del Pozo, M., Moro, E., Hernández, A. V. M., Castell, J. V., & Jover, R. (2024) · Toxicology · doi:10.1016/j.tox.2024.153974 · Cited by 1
Bischoff, K. L., Ramaiah, S. K., & Mukai, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29007-7.00040-6 · Cited by 2
Olaparib in pancreatic cancer: a computational study on safety and toxicological implications
Morais, G. C. D. F., Alves, G. B., Hossain, M. S., Sindi, E. R., Zaki, M. E. A., & Oliveira, J. I. N. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002523 · Cited by 1
Wang, Z., Wang, F., Huang, Y., Zhaxi, G., Fu, J., Song, G., Bai, B., Han, M., Zhang, J., Li, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1582435 · Cited by 1
Baskaran, U. L., Mukherjee, A. G., Sabina, E. P., Gopalakrishnan, A. V., & Vashishth, R. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70585 · Cited by 1
Exploring the toxicity mechanisms and detoxification methods of Rhizoma Paridis
Jianwei, S., Guowen, Z., Zhang, Y., Mengyang, Z., Zefei, D., & Haifeng, L. (2025) · Open Life Sciences · doi:10.1515/biol-2022-1055 · Cited by 1
Mechanistic insight into the role of lipoglycopeptide drugs in hepatotoxicity
Jha, A. K., Subramaniyan, V., Gupta, R., Saha, A., & Kumar, A. (2025) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2025.184497 · Cited by 1
Wang, X., Wang, Y., Hu, T., & Wang, K. (2026) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2026.05.009 · Cited by 1
Feng, H., Esposito, C., Benjak, A., Matter, M. S., Cieri, M., Carlo, C. D., Sedlaczek, P., Haak, F., Marinucci, M., Hess, G. F., et al. (2026) · Advanced Science · doi:10.1002/advs.202523976 · Cited by 1
Greene, N., & Gosink, M. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396461-8.00012-9 · Cited by 1
Yokoi, T. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.144.22 · Cited by 1
Recent Findings Regarding the Mechanism of Idiosyncratic Drug Toxicity
Ikeda, T. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00249-1 · Cited by 1
Perdices, E. V., Martín-Ocaña, F., Lucena, M. I., & Andrade, R. J. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70351-7 · Cited by 3
Can pharmacoeconomics and ethics be balanced in drug research and development?
Preziosi, P. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.6.513 · Cited by 1
[Safety of medicinal nanoproducts: new areas of toxicological research].
Grudziński, I. P. (2011) · PubMed · Cited by 1
Reactive Metabolite Screening and Covalent-Binding Assays
Hopfgartner, G. (2009) · CRC Press eBooks · doi:10.1201/9781420092219-c6 · Cited by 1
High-Content Screening: Understanding and Managing Mechanistic Data to Better Predict Toxicity
Walker, P., Smith, T., Frost, K., Kelly, S., & Suarez, I. G. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-2778-4_13 · Cited by 1
Idiosyncratic Adverse Reactions to Psychotropic Medications
Stevens, J. R., Rodgers, J. J., & Stern, T. A. (2016) · Psychiatric Annals · doi:10.3928/00485713-20160622-01 · Cited by 2
Solanas, E., Plá-Palacín, I., Sainz‐Arnal, P., de Almeida, M. B., Luè, A., Serrano, T., & Baptista, P. M. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-60511-1_2 · Cited by 1
Lin, C., Lee, S., Lee, M., & Dong, C. (2018) · Journal of Biomedical Optics · doi:10.1117/1.jbo.23.9.091407 · Cited by 1
Hepatotoxicidad inducida por clozapina: reporte de caso y revisión breve de la literatura
Revilla-Zúñiga, J. A., Carpio, J. C.-D., & Cruzado, L. (2021) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2021.04.010 · Cited by 1
Fulminant Hepatic Failure: Diagnosis and Management
Marzio, D. H., & Sass, D. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-05543-5_16-2 · Cited by 1
Gather and weigh the evidence when judging whether a drug has induced liver injury
&NA; (2007) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200723110-00008 · Cited by 1
Predicting drug-induced liver injury with artificial intelligence—a minireview
Li, T., Kusko, R. L., Thakkar, S., Liu, Z., & Tong, W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99136-0.00012-x · Cited by 3
Winterbourn, C. C., & Kettle, A. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00031-0 · Cited by 1
Suljević, D., Fočak, M., Škrijelj, R., & Mitrašinović‐Brulić, M. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4015 · Cited by 2
Hori, S., Taniguchi, H., Yoshimura, S., Takeda, K., Yamashita, R., Kimishima, A., & Harada, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00050 · Cited by 1
Yamazaki, Y., Kikuchi, K., Yamada, Y., Neo, S., Nitta, S., Igarashi, H., Kamiya, A., & Hisasue, M. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.09.003 · Cited by 2
Understanding Adverse Drug Effects and The Clinical Pharmacist's Role in Their Management
Tanin, F. A. (2024) · Journal of Natural Science Review · doi:10.62810/jnsr.v2i4.106 · Cited by 2
Hepatoprotective effects of quercetin against natural and chemical toxicities: A review
Bagheri, S., Tabeshpour, J., Hosseinzadeh, H., Hashemzaei, M., & Karimi, G. (2020) · Interdisciplinary Toxicology · doi:10.2478/intox-2020-0011 · Cited by 1
Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Lee, H.-K., & Lewis, L. D. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-283-4_15 · Cited by 1
“Non-chemical” drugs: biologicals, protein therapeutics, vaccines and antisense therapeutics
Müller, M. (2010) · Springer eBooks · doi:10.1007/978-3-7091-0144-5_20 · Cited by 1
Drug-Induced Liver Disease (DILI)
Polson, J., & Chalasani, N. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547416.012 · Cited by 1
De-Risking Drug Discovery Programmes Early with ADMET
Tsaioun, K., & Steven, A. (2011) · InTech eBooks · doi:10.5772/27764 · Cited by 1
Kuno, S., Sakurai, F., Shimizu, K., Matsumura, N., Kim, S., Watanabe, H., Tashiro, K., Tachibana, M., Yokoi, T., & Mizuguchi, H. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-109 · Cited by 1
Rao, C. V., Singh, A., Kumar, G., Gupta, S. S., Singh, S., & Rawat, A. K. S. (2015) · American journal of phytomedicine and clinical therapeutics · Cited by 4
Da, B. L., Yakov, G. B., Kleiner, D. E., & Koh, C. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0407-9 · Cited by 3
Bioengineering of Liver Tissue
Sainz‐Arnal, P., Plá-Palacín, I., Sánchez‐Romero, N., de Almeida, M. B., Morini, S., Solanas, E., Luè, A., Serrano, T., & Baptista, P. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00062-x · Cited by 4
Initial Toxicity Screening Techniques of Skin Contact Materials Using Glutathione
Heo, H., An, M.-J., Yoon, M.-S., & Park, Y. (2019) · Asian Journal of Beauty and Cosmetology · doi:10.20402/ajbc.2019.0271 · Cited by 1
How Mechanism Knowledge Can Help to Management of Drug Hypersensitivity
Ariza, A., Fernández, T. D., Bogas, G., Torres, M. J., & Mayorga, C. (2020) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00244-0 · Cited by 1
Pathogenetic mechanisms of drug-induced liver damage
Кочетков, А. И., Сергеевна, А. Е., & Ostroumova, O. D. (2020) · Siberian medical review · doi:10.20333/2500136-2020-6-36-50 · Cited by 4
Medikamentös-toxische Leberschädigung und Immuncheckpointinhibitor-induzierte Hepatitis
Bartl, S., Dinkhauser, P., & Hofer, H. (2021) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-021-00100-1 · Cited by 1
Liver Injury Due to Drugs and Herbal Agents
Kleiner, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-42873-6.00023-8 · Cited by 2
Inflammation and Organ Failure
Pruett, S. B., Tan, W., Sebastian, T., & Liu, D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00617-5 · Cited by 1
Inflammation and Drug‐Induced Liver Injury
Roth, R. A., & Ganey, P. E. (2009) · doi:10.1002/9780470747919.ch47 · Cited by 1
Applications of Pharmacogenetics in Pharmaceutical Research and Development
Burns, D. K., & Sundseth, S. S. (2012) · Wiley eBooks · doi:10.1002/9781118116494.ch16 · Cited by 1
Idiosyncratic Drug Reactions and the Potential Role of Metabolism
Uetrecht, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm128 · Cited by 1
Toxicology and Adverse Drug Reactions
Snodin, D. J., & Suitters, A. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch3 · Cited by 1
Adverse Drug Reactions in Dogs – Toxic Hepatic Responses
Woodward, K. (2009) · Wiley eBooks · doi:10.1002/9781444322958.ch18 · Cited by 1
In Vitro Models for the Prediction of Drug‐Induced Liver Injury in Lead Discovery
Moulin, F., & Flint, O. P. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch07 · Cited by 2
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.